Buprenorphine-naloxone maintenance following release from jail

Substance Abuse

Volumn 33, Issue 1, 2012, Pages 40-47

  Lee, Joshua D ^a   Grossman, Ellie ^a   Truncali, Andrea ^a   Rotrosen, John ^a   Rosenblum, Andrew ^b   Magura, Stephen ^c   Gourevitch, Marc N ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^c WESTERN MICHIGAN UNIVERSITY   (United States)

Author keywords

Buprenorphine; criminal justice; opioid dependence; primary care; re entry

Indexed keywords

BUPRENORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; OPIATE ADDICTION; PRIMARY HEALTH CARE; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NALOXONE; NARCOTIC ANTAGONISTS; NEW YORK CITY; OPIOID-RELATED DISORDERS; PRIMARY HEALTH CARE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856833558     PISSN: 08897077     EISSN: 15470164     Source Type: Journal    
DOI: 10.1080/08897077.2011.620475     Document Type: Article

References (20)

1. Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4586 Findings). Rockville, MD: Substance Abuse andMental Health Services Administration; 2010.
2. Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: A Treatment Improvement Protocol (TIP) Series 40.Rockville,MD: SubstanceAbuse andMental Health Services Administration; 2004.
3. Fiellin DA, Kleber H, Trumble-Hejduk JG, McLellan AT, Kosten TR. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat. 2004;27:153-159.
4. Reynaud-Maurupt C, Caer Y, Escaffre N, et al. High-dose buprenorphine substitution during incarceration. Presse Med. 2005;34:487-490.
5. Garcia CA, Correa GC, Viver AD, et al. Buprenorphine-naloxone treatment for pre-release opioiddependent inmates in Puerto Rico. J Addict Med. 2007;1:126-132.
6. Magura S, Lee JD, Hershberger J, et al. Buprenorphine and methadone maintenance in jail and postrelease: a randomized clinical trial. Drug Alcohol Depend. 2009;99:222-230.
7. Magura S, Rosenblum A, Lewis C, Joseph H. The effectiveness of in-jail methadone maintenance. J Drug Issues. 1993;23:76-99.
8. Tomasino V, Swanson AJ, Nolan J, Shuman H. The Key Extended Entry Program (KEEP): a methadone treatment program for opiate-dependent inmates. Mt Sinai J Med. 2001;68:14-20.
9. Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend. 2003;72:59-65.
10. Kinlock TW, Gordon MS, Schwartz RP, O'Grady K, Fitzgerald TT,Wilson M. A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depend. 2007;91:220-227.
11. Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009;105(1-2):83-88.
12. Heyman B. The hospital secure unit. In: Puisis M, ed. Clinical Practice in Correctional Medicine. St. Louis, MO: Mosby; 1998.
13. Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in communitybased primary care settings. Ann Fam Med. 2007;5:146-150.
14. Alford DP, LaBelle CT, Richardson JM, et al. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med. 2007;22:171-176.
15. Fiellin DA, Moore BA, Sullivan LE, et al. Longterm treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict. 2008;17:116-120.
16. Cunningham C, Giovanniello A, Sacajiu G, et al. Buprenorphine treatment in an urban community health center: what to expect. Fam Med. 2008;40:500-506.
17. Lee JD, Grossman E, DiRocco D, Gourevitch MN. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med. 2009;24:226-232.
18. Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;16(2):CD002207.
19. Binswanger IA, Stern MF, Deyo RA, et al. Release from prison-a high risk of death for former inmates. N Engl J Med. 2007;356:157-165.
20. Bird SM, Hutchinson SJ. 2003. Male drugs-related deaths in the fortnight after release from prison: Scotland, 1996-99. Addiction. 2003;98:185-190.